Newamsterdam Pharma Stock Performance
| NAMSW Stock | 12.50 1.39 10.01% |
NewAmsterdam Pharma holds a performance score of 7 on a scale of zero to a hundred. The company secures a Beta (Market Risk) of 0.0368, which conveys not very significant fluctuations relative to the market. As returns on the market increase, NewAmsterdam Pharma's returns are expected to increase less than the market. However, during the bear market, the loss of holding NewAmsterdam Pharma is expected to be smaller as well. Use NewAmsterdam Pharma sortino ratio, semi variance, as well as the relationship between the Semi Variance and day median price , to analyze future returns on NewAmsterdam Pharma.
Risk-Adjusted Performance
7 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in NewAmsterdam Pharma are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of fairly uncertain basic indicators, NewAmsterdam Pharma showed solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 467.7 M |
NewAmsterdam |
NewAmsterdam Pharma Relative Risk vs. Return Landscape
If you would invest 864.00 in NewAmsterdam Pharma on October 22, 2024 and sell it today you would earn a total of 386.00 from holding NewAmsterdam Pharma or generate 44.68% return on investment over 90 days. NewAmsterdam Pharma is currently producing 1.2474% returns and takes up 13.2396% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than NewAmsterdam, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
NewAmsterdam Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for NewAmsterdam Pharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as NewAmsterdam Pharma, and traders can use it to determine the average amount a NewAmsterdam Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0942
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | NAMSW | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 13.24 actual daily | 96 96% of assets are less volatile |
Expected Return
| 1.25 actual daily | 24 76% of assets have higher returns |
Risk-Adjusted Return
| 0.09 actual daily | 7 93% of assets perform better |
Based on monthly moving average NewAmsterdam Pharma is performing at about 7% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of NewAmsterdam Pharma by adding it to a well-diversified portfolio.
NewAmsterdam Pharma Fundamentals Growth
NewAmsterdam Stock prices reflect investors' perceptions of the future prospects and financial health of NewAmsterdam Pharma, and NewAmsterdam Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on NewAmsterdam Stock performance.
| Return On Equity | -0.47 | ||||
| Return On Asset | -0.29 | ||||
| Operating Margin | (0.86) % | ||||
| Revenue | 12.76 M | ||||
| EBITDA | (176.86 M) | ||||
| Total Debt | 60 K | ||||
| Book Value Per Share | 4.11 X | ||||
| Cash Flow From Operations | (141.22 M) | ||||
| Total Asset | 347.1 M | ||||
| Retained Earnings | (316.97 M) | ||||
About NewAmsterdam Pharma Performance
Evaluating NewAmsterdam Pharma's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if NewAmsterdam Pharma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if NewAmsterdam Pharma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Things to note about NewAmsterdam Pharma performance evaluation
Checking the ongoing alerts about NewAmsterdam Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for NewAmsterdam Pharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| NewAmsterdam Pharma is way too risky over 90 days horizon | |
| NewAmsterdam Pharma appears to be risky and price may revert if volatility continues | |
| NewAmsterdam Pharma has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 12.76 M. Net Loss for the year was (176.94 M) with profit before overhead, payroll, taxes, and interest of 33.59 M. | |
| NewAmsterdam Pharma generates negative cash flow from operations | |
| NewAmsterdam Pharma has a frail financial position based on the latest SEC disclosures |
- Analyzing NewAmsterdam Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether NewAmsterdam Pharma's stock is overvalued or undervalued compared to its peers.
- Examining NewAmsterdam Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating NewAmsterdam Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of NewAmsterdam Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of NewAmsterdam Pharma's stock. These opinions can provide insight into NewAmsterdam Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for NewAmsterdam Stock Analysis
When running NewAmsterdam Pharma's price analysis, check to measure NewAmsterdam Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NewAmsterdam Pharma is operating at the current time. Most of NewAmsterdam Pharma's value examination focuses on studying past and present price action to predict the probability of NewAmsterdam Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NewAmsterdam Pharma's price. Additionally, you may evaluate how the addition of NewAmsterdam Pharma to your portfolios can decrease your overall portfolio volatility.